60.22USD+0.89%Mkt Cap: 6.46B USDP/E: 172.06Last update: 2026-05-22
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap6.46B USD
Enterprise Value6.08B USD
Revenue (TTM)769.10M USD
Gross Profit748.43M USD
Net Income (TTM)99.65M USD
Revenue/Share7.399 USD
Last Price60.22 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees730
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)172.06
P/E (Forward)36.62
PEG0.81
EV/EBITDA-876.61
EV/Revenue7.90
P/S8.33
P/B10.04
EPS (TTM)0.35
EPS (Forward)1.63
52W Range
28.6651% of range91.00
52W High91.00 USD
52W Low28.66 USD
Profitability
Gross Margin98.30%
Oper. Margin-30.08%
EBITDA Margin-0.90%
Profit Margin13.09%
ROE15.38%
ROA11.91%
Growth
Revenue Growth4.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF142.00M USD
CapEx (TTM)211.00K USD
FCF Margin15.04%
FCF Yield1.79%
Net Debt-328.55M USD
Net Debt/EBITDA47.38
Balance Sheet
Debt/Equity0.01
Current Ratio2.86
Quick Ratio2.53
Book Value/Sh5.944 USD
Cash/Share3.150 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)79.00 USD
Target Range50.00 USD – 110.00 USD
# Analysts5
Ownership
Shares Out.107.35M
Float88.98M
Insiders11.54%
Institutions75.76%
Short Interest
Short Ratio9.6d
Short % Float12.88%
Short % Out.9.98%
Shares Short10.71M
Short (prev mo.)12.45M
Technical
SMA 5044.80 (+34.4%)
SMA 20059.65 (+0.9%)
Beta0.35
S&P 52W Chg28.31%
Avg Vol (30d)1.16M
Avg Vol (10d)1.23M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—